AI assistant
Eledon Pharmaceuticals, Inc. — Director's Dealing 2015
Sep 4, 2015
33900_dirs_2015-09-04_f22c824d-bc94-444a-a8c1-06be04b07efe.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Tokai Pharmaceuticals Inc (TKAI)
CIK: 0001404281
Period of Report: 2015-09-02
Reporting Person: Kalowski Lee (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2015-09-02 | Common Stock | S | 2158.00 | $12.96 | Disposed | 45621.00 | Direct |
Footnotes
F1: Shares were sold to satisfy certain tax obligations of the Reporting Person triggered by the vesting of certain restricted stock units. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.95 to $12.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: Represents 4,668 shares of common stock held by the Reporting Person and 40,953 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock upon vesting.